| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.075 | 0.08 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.073 | 0.08 |
| mRNA | selumetinib:vorinostat (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.074 | 0.08 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.08 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.09 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.11 | 0.09 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.3 | 0.09 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.09 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.071 | 0.09 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.087 | 0.09 |